"Alnespirone"

an anxiety disorder diagnosis, iii) subject with anxiety as a specifier of another psychiatric condition and not primarily diagnosed.Intervention(s), exposure(s)Inclusion criteria: i) any azapirone (e.g., alnespirone, binospirone, buspirone, enilospirone, eptaspirone, gepirone, ipsapirone, revospirone, tandospirone, zalospirone), ii) any route of administration (e.g., oral, transdermal, others)Exclusion of Bias assessment will be presented in the discussion.Analysis of subgroups or subsetsRegarding efficacy analyses, we will perform subgroup analyses, considering different molecules (e.g., alnespirone, binospirone, buspirone, enilospirone, eptaspirone, gepirone, ipsapirone, revospirone, tandospirone, zalospirone), considering different comparators (e.g., SSRI, TCA, single molecules), when

populationsIntervention(s), exposure(s)Inclusion criteria: i) azapirones (e.g., alnespirone, binospirone, buspirone, enilospirone, eptaspirone, gepirone, ipsapirone, revospirone, tandospirone, zalospirone)Exclusion criteria: i) non-azapirone drugsComparator(s)/controlInclusion criteria: i) placebo ii) other active pharmacological treatments iii) Therapy as usual for augmentation trialsExclusion criteria: i